Dr. Melissa Ann Stevens, D.D.S. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 220 S. Cliff Ave., Ste. 104, Harrisburg, SD 57032 Phone: 605-767-0285 |
Lauren M Schroeder, DDS Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 225 N Cliff Ave Ste 2, Harrisburg, SD 57032 Phone: 605-213-1230 |
Sean Rasmusson Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 220 S Cliff Ave, Harrisburg, SD 57032 Phone: 605-767-0285 |
Seth Thomas Schroeder, DDS Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 225 N Cliff Ave Ste 2, Harrisburg, SD 57032 Phone: 605-213-1230 |
News Archive
Inhibitex, Inc. today announced that the independent data safety monitoring board (DSMB) responsible for reviewing safety data from the Company's ongoing Phase II clinical trial of FV-100 met, as scheduled, after the Company had provided it with complete 30-day follow-up safety data on the third quartile (75%) of the patients that the Company plans to enroll in the trial. Based upon its review, the DSMB recommended that the trial continue to completion without modification.
When it comes to dietary nutrients, most consumers don't know the whole story. A recent study by the Innovation Center for U.S. Dairy revealed that the fact that milk delivers much more than calcium to the diet is new "news" to consumers.
P.A.D. occurs when arteries in the legs become narrowed or clogged with fatty deposits, reducing blood flow to the legs. This can result in leg muscle pain when walking, disability, amputation, and poor quality of life. Blocked arteries found in people with P.A.D. can be a red flag that other arteries, including those in the heart and brain, may also be blocked - increasing the risk of a heart attack or stroke.
CTS Corporation today announced fourth quarter 2009 revenues of $133.9 million, 6% higher than third quarter 2009 revenues of $126.6 million. Fourth quarter 2009 net earnings were $4.1 million, or $0.12 per diluted share, including a discrete tax valuation allowance charge of $2.5 million (or $0.07 per diluted share). Excluding this charge, fourth quarter non-GAAP adjusted net earnings were $6.6 million, or $0.19 per diluted share, compared to third quarter 2009 net earnings of $4.5 million, or $0.13 per diluted share.
› Verified 8 days ago